ClinicalTrials.gg
Not yet recruitingNCT04763993ReBvSSUpdated Nov 12, 2026

Reflux Disease After Gastric Bypass Versus Sleeve Gastrectomy in Morbid Obese Patients: an Italian Study

An interventional study of Roux-en-Y-Gastric bypass, Sleeve gastrectomy and SG in Gastroesophageal Reflux Disease and Obesity, sponsored by Niguarda Hospital. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Niguarda Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 12, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The study aims to clarify if GERD, defined by results of 24 hours potential of hydrogen (pH) monitoring and abnormal DeMeester Score (DMS), in obese patients could worsen after Sleeve Gastrectomy (SG) more than after RYGBP. To demonstrate this hypothesis, the investigators will study the obese population suspected for GERD with 24 hours monitoring and High-Resolution Esophageal Manometry (HRM). DMS is calculated pre-operatively and, once GERD is confirmed, the patients are enrolled for randomization to SG or RYGBP. The suspicion of GERD is investigated with the GERDQ score and EGDS, that all obese patients have pre-operatory.

Read the detailed description

Obesity is an independent risk factor for GERD and its complications. Bariatric surgery is effective in treatment of obesity and at the same time in controlling GERD, but there is disparity in current literature if sleeve gastrectomy could worsen it, more than gastric bypass. Our study aims to investigate if there is a difference in postoperative GERD between these two surgical procedures in obese patients with pre-existing GERD, defined by results of 24 hours pH monitoring, expressed by an abnormal DeMeester Score (DMS). REBvSS is a monocentric randomized controlled trial (RCT). The investigators will study 128 obese patients, eligible for Bariatric Surgery (BMS), suspected for GERD, with 24-h pH monitoring and high-resolution manometry. DMS is calculated pre-operatively and, once GERD is confirmed, the patients are randomized to SG or RYGBP. The DMS is then calculated on 24 hours pH monitoring 24 months after the surgery and the degree of GERD is evaluated. The promoter centre is the Division of Minimally invasive Oncological General Surgery at Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan, Lombardy, that is an excellence centre for bariatric and metabolic surgery according to Società Italiana di Chirurgia dell'Obesità e delle malattie metaboliche (SICOB) accreditation policy, where the study will be carried out.

Medical history will be collected during the first outpatient examination and assessed as follows:

  • Diagnosis of Obesity, based on value of BMI ≥ 35;
  • Investigation of obesity-related diseases
  • Clinical, nutritional and surgical history
  • GERDQ score If the patient is eligible for BMS and there is the suspicion of GERD the preoperative evaluation will be carried out. It consists of a trial specific evaluation (EGDS, 24-h pH monitoring, HRM, DMS), that confirms the presence of GERD, and a standard evaluation (Ultrasonography of abdomen, ECG, Chest X-Ray, Blood exams, anesthaesiologic evaluation). When all the inclusion criteria are verified, the patient will be randomized to RYGBP or SG group and will undergo surgery. All patients will be randomized centrally using an online computer controlled permuted-block randomization module between SG and RYGBP in a 1:1 ratio.

The postoperative visits will be organised as follow:

  • 90 days after surgery, to evaluate the presence or the absence of medical or surgical complications;
  • 12 months and 24 months after surgery EGDS, 24 hours pH-monitoring and HRM will be performed to evaluate the degree of esophagitis and calculate the DMS; the quality of life and the symptoms will be assessed troughs BAROS and GERDQ score; also the trend of comorbidities will be examined.

Every patient will be analysed according to the allocated treatment. The investigators hope that our study will finally answer this issue, thanks to its randomized nature and the definition of GERD based on gold standard pH monitoring. These findings might influence decision-making in bariatric surgery and change or confirm the success of sleeve gastrectomy, also for what concerns the reflux disease.

02

Conditions studied

  • Gastroesophageal Reflux Disease
  • Obesity

Keywords

  • Gastroesophageal Reflux Disease
  • Obesity
  • Sleeve gastrectomy
  • Gastric bypass
  • DeMeester score
  • pH-monitoring
03

In context

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

This study's planned enrollment of 128 is above the median of 68 across 800 interventional studies indexed under Gastroesophageal Reflux.

Browse Gastroesophageal Reflux studies →

Lead sponsor

Niguarda Hospital is the lead sponsor of 68 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acceptance of randomization to surgery;
  • Participant is willing and able to give for participation in the trial;
  • Written informed consent;
  • Compliance to follow-up;
  • Male and female;
  • ≥18 and ≤70 years old;
  • ≥ 35 with obesity-related comorbidities;
  • BMI ≥ 40 with or without obesity-related comorbidities;
  • GERDQ score ≥ 3 points;
  • Use of proton pump inhibitor;
  • Mild and Moderate GERD (DMS ≥14.72 ≤100)
  • Incompetence of the Esophagogastric junction
  • Los Angeles grade A, B, C, D esophagitis.

Exclusion criteria

Exclusion criteria

  • Medical or psychiatric conditions that compromises the patient's ability to give or comply with the study protocol;
  • Barrett's esophagus (BE);
  • Spastic motor disorders and esophageal hypomotility;
  • Peptic strictures;
  • Absence of GERD (DMS\<14.72);
  • Severe GERD (DMS>100);
  • Hiatal hernia > 5 cm;
  • Previous bariatric surgery or major general surgery;
  • Type 2 diabetes (T2D) for more than > 5 years;
  • Necessity to explore stomach, the duodenum or the biliary tract;
  • Refuse of randomization;
  • Personal reasons.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
128 participants (estimated)

Study arms

  • Active comparator
    RYGBP

    RYGBP: Roun-en-Y Gastric Bypass

    Procedure: Roux-en-Y-Gastric bypass, Sleeve gastrectomy · Procedure: SG

  • Experimental
    SG

    SG: Sleeve Gastrectomy

    Procedure: Roux-en-Y-Gastric bypass, Sleeve gastrectomy · Procedure: SG

Interventions

  • ProcedureRoux-en-Y-Gastric bypass, Sleeve gastrectomy

    RYGBP consists in creating a small gastric pouch along the little curvature of the stomach, followed by the section of the small bowel. The restoration of the gastro-intestinal tract is achieved by performing a gastro-jejunal and a jejuno-jejunal anastomosis, giving this procedure the characteristic aspect of a Y. Also, for RYGBP the laparoscopic approach requires the placement of 5 trocars in the upper part of the abdomen.

  • ProcedureSG

    SG consists in removing the fundus and the body of the stomach, along the greater curvature. To perform it with a laparoscopic approach, we create the pneumoperitoneum with Veress needle and place 5 trocars in the upper part of the abdomen. The first step is the dissection of the greater curvature of the stomach, that starts at 6 centimetres from pylorus and it's conducted up to the angle of His, freeing the fundus and exposing the left pillar. A 38 Fr bougie is placed inside the stomach to calibrate its section. After it is carried out, the specimen is removed from the greater trocar site.

06

What researchers measure

Primary outcomes

  1. Change of the pre-existing Gastro-Esophageal Reflux Disease (GERD) from baseline in patients underwent SG and RYGBP

    GERD will be evaluated performing 24-h pH monitoring before the surgery. The presence and the degree of GERD will be quantified calculating the DeMeester Score (DMS): * DMS \< 14.72 there is no evidence of GERD; * DMS 14.72 - 50 mild GERD; * DMS 50 - 100 moderate GERD; * DMS \> 100 severe GERD An upgrading in DMS class will determine a worsening in GERD

    Time frame: Change from baseline DeMeester Score 24 months after surgery

Secondary outcomes

  1. Postoperative Gastroesophageal Reflux Disease (GERD) from baseline

    The degree of GERD will be quantified calculating the DeMeester Score (DMS): * DMS \< 14.72 there is no evidence of GERD; * DMS 14.72 - 50 mild GERD; * DMS 50 - 100 moderate GERD; * DMS \> 100 severe GERD An upgrading in DMS class will determine a worsening in GERD

    Time frame: Change from baseline DeMeester Score 12 months after surgery

  2. Postoperative reflux symptoms

    Expressed by Gastroesophageal Reflux Disease Questionnaire (GERDQ) Scoring How many times per week do each of the following symptoms occur per week Score 0: Occurs on 0 days Score 1: Occurs on 1 day Score 2: Occurs on 2-3 days Score 3: Occurs on 4-7 days Questions (Score 0-3 for each based on above) Burning feeling behind the Breastbone (Heartburn)? Stomach contents moving up to the throat or mouth (regurgitation)? Pain in the middle of the upper Stomach area? Nausea? Trouble getting a good night's sleep because of Heartburn or regurgitation? Need for over-the-counter medicine for Heartburn or regurgitation? Examples: Tums, Rolaids, Maalox, or other Antacids) In addition to the medicine your doctor prescribed Interpretation Total score of 0-2 points Likelihood of GERD: 0 percent Total score of 3-7 points Likelihood of GERD: 50 percent Total score of 8-10 points Likelihood of GERD: 79 percent Total score of 11-18 points Likelihood of GERD: 89 percent

    Time frame: Baseline and 12 and 24 months from the surgery

  3. Quality of life Questionnaire

    Expressed by Bariatric Analysis and Reporting Outcome System (BAROS) Score, calculated after 12 and 24 months from the surgery. The scoring key is assessed as follows: Failure ≤1 point; Fair \> 1 to 3 points; Good \> 3 to 5 points; Very Good \> 5 to 7 points; Excellent \> 7 to 9 points

    Time frame: month 12 and 24 after surgery

  4. Trend of the obesity-related diseases (Arterial hypertension, Type 2 Diabetes, continuous positive airway pressure (CPAP) use

    Anti-hypertensive drugs (AH) taken before surgery:stability=no change in AH,resolution= no AH,improvement=decrease in AH,worsening=increase in AH In no hypertension pts before surgery;new onset=introduction of AH Oral anti-glycemic (AG) medication taken before surgery:Stability=no change in number of oral AG.Resolution=defined as no oral AG,Improvement=decrease in number of oral AG,Worsening=increase in number of oral AG or switch to insulin-dependence In pts with insulin dependence before surgery:Stability=no change in number of insulin units,Resolution=no anti-diabetic therapy,Improvement=decrease in number of insulin units or oral AG,Worsening=increase in number of insulin units In pts not affected by type 2 diabetes before surgery:new onset=introduction of anti-diabetic therapy In pts using CPAP before surgery:Stability=continued use of CPAP,Resolution=discontinued use of CPAP In pts not affected by obstructive sleep apnea syndrome (OSAS) before surgery:new onset=use of CPAP

    Time frame: month 12 and 24 after surgery

  5. Demographic

    Demographic data

    Time frame: Enrollment

  6. Medical/Surgical complications

    The number of patients that experienced medical and/or surgical complications within 90 days from surgery, graded according to Clavien-Dindo classification (grade I, II, IIIa, IIIb, Iva, IVb, V)

    Time frame: day 90

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2027; primary completion for May 2028, 12 months later.

Of 194 non-industry interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 68. This study's planned 12 months is below that.

Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → May 2027, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2021
First posted
Feb 21, 2021
StartEst.
May 1, 2027was May 2026
Primary completionEst.
May 1, 2028
CompletionEst.
May 1, 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 1, 2026→May 1, 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Start date May 1, 2026→May 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04763993
Lead sponsor
Niguarda Hospital
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
May 1, 2027 (estimated)
Primary completion
May 1, 2028 (estimated)
Completion
May 1, 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Gisella Barone, MD
Contact
gisella.barone89@gmail.com
+39 026444 ext. 7918
Valerio Girardi, MD
Contact
valerio.girardi@ospedaleniguarda.it
+39 026444 ext. 7918

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion